VeriStrat Proteomic Test Approved by NCCN for Inclusion in NSCLC Treatment

NCCN recommended the diagnostic proteomic test to identify patients who can receive erlotinib as second-line therapy.

Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, today announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).

NCCN Guidelines provide evidence-based, consensus-driven management recommendations that seek to ensure all patients receive preventive, diagnostic, treatment and supportive services that are most likely to lead to optimal outcomes.

The updated NCCN Guidelines recommend clinicians’ use of VeriStrat — a non-invasive, blood-based protein profiling test — to help determine whether patients entering the second line of treatment for NSCLC should be considered as candidates to receive the targeted drug erlotinib (Tarceva®), which offers fewer side effects and greater convenience over standard chemotherapy. The NCCN guidelines state: “Recommended proteomic testing for patients with NSCLC and wild-type EGFR or with unknown EGFR status. A patient with a ‘poor’ classification should not be offered erlotinib in the second-line setting.”

Read the full press release: http://bit.ly/1FMkzF5